

**NDA 50-749/S-002**

Parke-Davis Pharmaceutical Research  
Attention: Drusilla Scott, Ph.D.  
Director, Worldwide Regulatory Affairs  
2800 Plymouth Road  
P.O. Box 1047  
Ann Arbor, MI 48106-1047

Dear Dr. Scott:

Please refer to your supplemental new drug application dated July 14, 1998, received July 15, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Omnicef® (cefdinir) Powder for Oral Suspension. We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated November 9, 1998, December 16, 1998, December 18, 1998, February 22, 1999, May 17, 1999, and July 8, 1999.

This supplemental new drug application provides for the use of Omnicef® (cefdinir) Powder for Oral Suspension for a 5-day dosing regimen (7 mg/kg BID) for the treatment of acute bacterial otitis media.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-749/S-002." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We note that you have fulfilled the pediatric study requirement at this time.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Beth Duvall-Miller, Project Manager, at (301) 827-2125.

Sincerely yours,

Gary K. Chikami, M.D.  
Director  
Division of Anti-Infective Drug Products  
Office of Drug Evaluation IV  
Center for Drug Evaluation and Research

Enclosure